Mislav Vrsalović1,2, Ana Vrsalović Presečki3. 1. University of Zagreb School of Medicine, Zagreb, Croatia. 2. Department of Cardiology, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia. 3. Faculty of Chemical Engineering and Technology, University of Zagreb, Zagreb, Croatia.
Abstract
BACKGROUND: Atrial fibrillation (AF) is associated with adverse outcomes in terms of survival and morbidity. Peripheral artery disease (PAD) and AF share several common risk factors and often coexist. Whether AF has a prognostic role in patients with PAD has not been extensively studied. HYPOTHESIS: AF is associated with major adverse cardiac events (MACE) and mortality in symptomatic PAD patients. METHODS: Using MEDLINE and Scopus, we searched for studies published before December 2016 that evaluated cardiovascular outcomes based on the presence/absence of AF in a prospective manner with a follow-up period of ≥12 months. The outcomes were reported using a random-effects model, and heterogeneity was assessed using the I2 statistic. Sensitivity analyses were performed to test the contribution of each study to the overall results. RESULTS: Six prospective studies (Newcastle-Ottawa score range, 7-9) with 14 656 patients were included in the final analysis (age range, 66-70 years; median follow-up, 1.4 years). Our pooled analysis found a significant association between AF and mortality (odds ratio: 2.52, 95% confidence interval: 1.91-3.34, I2 = 32.6%), without evidence of publication bias (P = 0.63). Meta-analysis showed a significant impact of AF on MACE (odds ratio: 2.54, 95% confidence interval: 1.78-3.63, I2 = 74.3%), without detected publication bias (P = 0.08). CONCLUSIONS: AF is associated with increased risk of mortality and MACE in symptomatic PAD.
BACKGROUND:Atrial fibrillation (AF) is associated with adverse outcomes in terms of survival and morbidity. Peripheral artery disease (PAD) and AF share several common risk factors and often coexist. Whether AF has a prognostic role in patients with PAD has not been extensively studied. HYPOTHESIS: AF is associated with major adverse cardiac events (MACE) and mortality in symptomatic PAD patients. METHODS: Using MEDLINE and Scopus, we searched for studies published before December 2016 that evaluated cardiovascular outcomes based on the presence/absence of AF in a prospective manner with a follow-up period of ≥12 months. The outcomes were reported using a random-effects model, and heterogeneity was assessed using the I2 statistic. Sensitivity analyses were performed to test the contribution of each study to the overall results. RESULTS: Six prospective studies (Newcastle-Ottawa score range, 7-9) with 14 656 patients were included in the final analysis (age range, 66-70 years; median follow-up, 1.4 years). Our pooled analysis found a significant association between AF and mortality (odds ratio: 2.52, 95% confidence interval: 1.91-3.34, I2 = 32.6%), without evidence of publication bias (P = 0.63). Meta-analysis showed a significant impact of AF on MACE (odds ratio: 2.54, 95% confidence interval: 1.78-3.63, I2 = 74.3%), without detected publication bias (P = 0.08). CONCLUSIONS:AF is associated with increased risk of mortality and MACE in symptomatic PAD.
Authors: Michal Tendera; Victor Aboyans; Marie-Louise Bartelink; Iris Baumgartner; Denis Clément; Jean-Philippe Collet; Alberto Cremonesi; Marco De Carlo; Raimund Erbel; F Gerry R Fowkes; Magda Heras; Serge Kownator; Erich Minar; Jan Ostergren; Don Poldermans; Vincent Riambau; Marco Roffi; Joachim Röther; Horst Sievert; Marc van Sambeek; Thomas Zeller Journal: Eur Heart J Date: 2011-08-26 Impact factor: 29.983
Authors: Gregory Y H Lip; Stephan Windecker; Kurt Huber; Paulus Kirchhof; Francisco Marin; Jurriën M Ten Berg; Karl Georg Haeusler; Giuseppe Boriani; Davide Capodanno; Martine Gilard; Uwe Zeymer; Deirdre Lane; Robert F Storey; Hector Bueno; Jean-Philippe Collet; Laurent Fauchier; Sigrun Halvorsen; Maddalena Lettino; Joao Morais; Christian Mueller; Tatjana S Potpara; Lars Hvilsted Rasmussen; Andrea Rubboli; Juan Tamargo; Marco Valgimigli; Jose L Zamorano Journal: Eur Heart J Date: 2014-08-25 Impact factor: 29.983
Authors: Jonas Bjerring Olesen; Gunnar Hilmar Gislason; Christian Torp-Pedersen; Gregory Y H Lip Journal: Clin Cardiol Date: 2012-01 Impact factor: 2.882
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Eduardo Aguilar; Ana María García-Díaz; Juan Francisco Sánchez Muñoz-Torrero; Lorenzo Ramón Alvarez; Mar Piedecausa; Gemma Arnedo; Manuel Monreal Journal: Thromb Res Date: 2012-05-31 Impact factor: 3.944
Authors: Shinya Goto; Deepak L Bhatt; Joachim Röther; Mark Alberts; Michael D Hill; Yasuo Ikeda; Shinichiro Uchiyama; Ralph D'Agostino; E Magnus Ohman; Chiau-Suong Liau; Alan T Hirsch; Jean-Louis Mas; Peter W F Wilson; Ramón Corbalán; Franz Aichner; P Gabriel Steg Journal: Am Heart J Date: 2008-09-23 Impact factor: 4.749
Authors: Jonas Bjerring Olesen; Gregory Y H Lip; Deirdre A Lane; Lars Køber; Morten Lock Hansen; Deniz Karasoy; Carolina Malta Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen Journal: Am J Med Date: 2012-05-10 Impact factor: 4.965
Authors: Benjamin Miao; Adrian V Hernandez; Yuani M Roman; Mark J Alberts; Craig I Coleman; William L Baker Journal: Clin Cardiol Date: 2020-02-27 Impact factor: 2.882